NyxoahNYXH
About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Employees: 184
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
39% more capital invested
Capital invested by funds: $39.1M [Q3] → $54.4M (+$15.3M) [Q4]
10% more funds holding
Funds holding: 20 [Q3] → 22 (+2) [Q4]
7.77% more ownership
Funds ownership: 11.95% [Q3] → 19.72% (+7.77%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Edward White 21% 1-year accuracy 31 / 147 met price target | 147%upside $15 | Buy Maintained | 26 Mar 2025 |
Stifel Jonathan Block 6% 1-year accuracy 1 / 18 met price target | 147%upside $15 | Buy Maintained | 14 Mar 2025 |
Financial journalist opinion
Based on 15 articles about NYXH published over the past 30 days
